ASX ANNOUNCEMENT 22 JULY 2024
FIRST PATIENT ENROLLED IN CHM CDH17 PHASE 1/2 CLINICAL TRIAL
Sydney, Australia, 22 July 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”
,
an Australian leader in cell therapy, is pleased to announce that the first participant has been
enrolled in the Phase 1/2 multi-centre clinical trial for CHM CDH17 cell therapy.
The Phase 1/2 trial (NCT06055439) is a two-stage study designed to determine a recommended
Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with
advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.
“This is great progress for this first-in-human study for bowel cancer patients with significant
unmet need; congratulations to the CHM team and our investigational sites on this milestone.”
said Dr Rebecca McQualter, Chief Operating Officer of Chimeric Therapeutics.
“It is exciting to see the advancement from the development of the CDH17 CAR T technology in
our laboratory to the enrollment of the first patient in this Phase 1/2 study,” said Xianxin Hua,
MD, PhD, Professor of Cancer Biology in Penn’s Perelman School of Medicine, an investigator at
the Abramson Family Cancer Research Institute and a Harrington Scholar Innovator.
Additional clinical trial sites are anticipated to open in the second half of 2024.
ALA EV worth 15 x more than CHM for having Zilch. CHM world leader in GBM - CAR-T and CDH17 killing solid tumours directly valued absolutely ZERO.
(20min delay)